摘要
目的 研究探讨早期脑梗死患者应用阿替普酶与尿激酶急溶栓联合治疗的应用效果及安全性。方法 选取我院2018年10月-2020年8月急性脑梗死患者100例作为研究对象,采用随机对照法分为研究组(n=50例)与对照组(n=50例),研究组患者使用阿替普酶溶栓治疗治疗,对照组患者使用尿激酶溶栓治疗。比较两组患者治疗前及治疗6h、1周、2周后神经功能缺损评分(NIHSS);比较两组患者治疗前后凝血功能指标;比较两组患者治疗后不同时间血管再通率及不良反应发生率。结果 两组患者治疗后NIHSS评分均低于治疗前评分(P<0.05),其中研究组治疗后NIHSS评分低于与对照组(P<0.05);研究组患者治疗后凝血功能指标高于对照组(P<0.05);研究组患者治疗3h、6h后及血管总再通率高于对照组(P<0.05);研究组治疗后不良反应总发生率低于对照组(P<0.05)。结论 阿替普酶应用于早期急性脑梗死患者溶栓治疗与尿激酶相比治疗效果更好,安全性更高。
Objective To investigate the effect and safety of emergency thrombolytic therapy with alteplase and urokinase in patients with early cerebral infarction.Methods Between October 2018 and August 2020,100 patients with acute cerebral infarction were selected and randomly divided into study group(n=50)and control group(n=50).The study group received thrombolytic therapy with alteplase, while the control group received thrombolytic therapy with urokinase.The National Institutes of Health Stroke Scale(NIHSS)scores, blood coagulation function indexes, the vascular recanalization rate and the incidence of adverse reactions were compared between the two groups.Results After treatment, NIHSS scores of the two groups were lower than those before treatment(P<0.05),and the study group had lower NIHSS scores than the control group(P<0.05).The coagulation function indexes in the study group were higher than those in the control group(P<0.05).The total vascular recanalization rate was higher in the study group than in the control group after 3 h and 6 h of treatment.The total incidence of adverse reactions was lower in the study group than in the control group(P<0.05).Conclusion Compared with urokinase, alteplase used in thrombolytic therapy for patients with early acute cerebral infarction can achieve a better therapeutic effect and higher safety.
作者
周江伟
Zhou Jiangwei(Sanmervxia Center Hospital,Sanmenxia,Henan 472000,China)
出处
《辽宁医学杂志》
2022年第3期7-10,共4页
Medical Journal of Liaoning
关键词
急性脑梗死
阿替普酶
尿激酶
早期溶栓
疗效
Acute cerebral infarction
Alteplase
Urokinase
Early thrombolysis
Efficacy
